Workforce Development & Leadership

Evolent Nominates Shawn Guertin to Board of Directors

Evolent
  • Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability.
  • Mr. Guertin’s nomination represents continuation of Evolent’s board refreshment efforts.

Evolent Health, Inc. (NYSE: EVH) (“Evolent”), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockholders scheduled to be held on June 5, 2025.

The Board has recommended Mr. Shawn Guertin for election. Mr. Guertin is an insurance and healthcare executive with nearly 40 years of actuarial, financial and management experience. Most recently, he served as Executive Vice President and Chief Financial Officer for CVS Health Corporation from May 2021 to October 2023.

Mr. Guertin’s nomination follows a search process by the Board’s Nominating and Governance Committee to refresh an independent director position.

“It is an honor to be nominated to the Board,” said Mr. Guertin. “I believe that Evolent offers a differentiated product for payers seeking to deliver top-quality clinical outcomes and health care value to members living with complex health conditions. I’m excited for the opportunity to help drive shareholder value.”  

If elected, Mr. Guertin will be the sixth new independent director added to the Board in the past four years, reflecting the Board’s emphasis on ensuring its corporate governance aligns with best-in-class practices.

“Shawn brings an impressive track record of driving growth and profitability in the healthcare industry, and we are excited about the opportunity to have him join the Board,” said Evolent  Board Chair Cheryl Scott.

Evolent Co-Founder and Chief Executive Officer Seth Blackley stated, “Shawn is a highly respected leader from some of America’s best-known healthcare brands. We look forward to benefiting from his guidance and his passion for our mission.”

Mr. Guertin would take the seat currently held by Diane Holder, who is not seeking re-election.

“I am incredibly grateful to Diane for her contributions to Evolent and the Board over the last 14 years. Diane has helped establish the company as a leader in value-based specialty care, and her legacy will always be linked to Evolent,” said Mr. Blackley.

Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!

Related posts

Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer

Business Wire

Foresight Diagnostics Expands Partnership with Allogene Abroad

PR Newswire

Arima Genomics Adds 3 Executives to Boost 3D Genomics Growth

Business Wire